Literature DB >> 29850989

LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice.

Alizée Latour1, Yuchen Gu1, Nadim Kassis1, Fabrice Daubigney1, Catherine Colin2, Blandine Gausserès1, Sandrine Middendorp1, Jean-Louis Paul3, Valérie Hindié4, Jean-Christophe Rain4, Jean-Maurice Delabar1, Eugene Yu5, Mariona Arbones6,7, Michel Mallat2, Nathalie Janel8,9.   

Abstract

Down syndrome is characterized by premature aging and dementia with neurological features that mimic those found in Alzheimer's disease. This pathology in Down syndrome could be related to inflammation, which plays a role in other neurodegenerative diseases. We previously found a link between the NFkB pathway, long considered a prototypical proinflammatory signaling pathway, and the dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). DYRK1A is associated with early onset of Alzheimer's disease in Down syndrome patients. Here, we sought to determine the role of DYRK1A on regulation of the NFkB pathway in the mouse brain. We found that over-expression of Dyrk1A (on a C57BL/6J background) stabilizes IκBα protein levels by inhibition of calpain activity and increases cytoplasmic p65 sequestration in the mouse brain. In contrast, Dyrk1A-deficient mice (on a CD1 background) have decreased IκBα protein levels with an increased calpain activity and decreased cytoplasmic p65 sequestration in the brain. Taken together, our results demonstrate a role of DYRK1A in regulation of the NFkB pathway. However, decreased IκBα and DYRK1A protein levels associated with an increased calpain activity were found in the brains of mice over-expressing Dyrk1A after lipopolysaccharide treatment. Although inflammation induced by lipopolysaccharide treatment has a positive effect on calpastatin and a negative effect on DYRK1A protein level, a positive effect on microglial activation is maintained in the brains of mice over-expressing Dyrk1A.

Entities:  

Keywords:  Calpain activity; DYRK1A; Down syndrome; IkB; Mouse brain; NFkB pathway

Mesh:

Substances:

Year:  2018        PMID: 29850989     DOI: 10.1007/s12035-018-1113-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  58 in total

Review 1.  Activators and target genes of Rel/NF-kappaB transcription factors.

Authors:  H L Pahl
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  DYRK1A: a master regulatory protein controlling brain growth.

Authors:  Fayçal Guedj; Patricia Lopes Pereira; Sonia Najas; Maria-Jose Barallobre; Caroline Chabert; Benoit Souchet; Catherine Sebrie; Catherine Verney; Yann Herault; Mariona Arbones; Jean M Delabar
Journal:  Neurobiol Dis       Date:  2012-01-26       Impact factor: 5.996

3.  Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).

Authors:  Woo-Joo Song; Eun-Ah Christine Song; Min-Su Jung; Sun-Hee Choi; Hyung-Hwan Baik; Byung Kwan Jin; Jeong Hee Kim; Sul-Hee Chung
Journal:  J Biol Chem       Date:  2014-12-04       Impact factor: 5.157

4.  Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.

Authors:  Soo-Ryoon Ryoo; Hyun-Jeong Cho; Hye-Won Lee; Hey Kyeong Jeong; Chinzorig Radnaabazar; Yeun-Soo Kim; Min-Jeong Kim; Mi-Young Son; Hyemyung Seo; Sul-Hee Chung; Woo-Joo Song
Journal:  J Neurochem       Date:  2007-11-14       Impact factor: 5.372

5.  NF-kappa B functions in synaptic signaling and behavior.

Authors:  Mollie K Meffert; Jolene M Chang; Brian J Wiltgen; Michael S Fanselow; David Baltimore
Journal:  Nat Neurosci       Date:  2003-08-31       Impact factor: 24.884

6.  N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation.

Authors:  Paloma Goñi-Oliver; José J Lucas; Jesús Avila; Félix Hernández
Journal:  J Biol Chem       Date:  2007-06-14       Impact factor: 5.157

Review 7.  NF-kappaB in the nervous system.

Authors:  Barbara Kaltschmidt; Christian Kaltschmidt
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09       Impact factor: 10.005

8.  Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome.

Authors:  Barbara Granese; Iris Scala; Carmen Spatuzza; Anna Valentino; Marcella Coletta; Rosa Anna Vacca; Pasquale De Luca; Generoso Andria
Journal:  BMC Med Genomics       Date:  2013-07-05       Impact factor: 3.063

Review 9.  Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans.

Authors:  Simon Vann Jones; Ilias Kounatidis
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

10.  Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.

Authors:  Fayçal Guedj; Catherine Sébrié; Isabelle Rivals; Aurelie Ledru; Evelyne Paly; Jean C Bizot; Desmond Smith; Edward Rubin; Brigitte Gillet; Mariona Arbones; Jean M Delabar
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

View more
  7 in total

1.  DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.

Authors:  Manon Moreau; Maria Carmona-Iragui; Miren Altuna; Lorraine Dalzon; Isabel Barroeta; Marie Vilaire; Sophie Durand; Juan Fortea; Anne-Sophie Rebillat; Nathalie Janel
Journal:  Biomedicines       Date:  2022-06-10

2.  Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.

Authors:  Gian Luca Araldi; Yu-Wen Hwang
Journal:  Bioorg Med Chem Lett       Date:  2022-03-12       Impact factor: 2.940

3.  Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain amyloid load.

Authors:  Jean M Delabar; Marion Ortner; Stephanie Simon; Anne Wijkhuisen; Cecile Feraudet-Tarisse; Jonathan Pegon; Emma Vidal; Yael Hirschberg; Bruno Dubois; Marie-Claude Potier
Journal:  Alzheimers Dement (N Y)       Date:  2020-07-02

4.  DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.

Authors:  Yangling Li; Dongmei Zhou; Shuang Xu; Mingjun Rao; Zuoyan Zhang; Linwen Wu; Chong Zhang; Nengming Lin
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

Review 5.  Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.

Authors:  Helin Atas-Ozcan; Véronique Brault; Arnaud Duchon; Yann Herault
Journal:  Genes (Basel)       Date:  2021-11-20       Impact factor: 4.096

6.  Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.

Authors:  Yuchen Gu; Gautier Moroy; Jean-Louis Paul; Anne-Sophie Rebillat; Mara Dierssen; Rafael de la Torre; Cécile Cieuta-Walti; Julien Dairou; Nathalie Janel
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

7.  Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome.

Authors:  Xu-Qiao Chen; Zhuo Xing; Quang-Di Chen; Richard J Salvi; Xuming Zhang; Benjamin Tycko; William C Mobley; Y Eugene Yu
Journal:  Front Aging Neurosci       Date:  2021-07-01       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.